Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;3(4):259-266.
doi: 10.2217/mmt-2016-0020. Epub 2016 Nov 29.

Advances in the development of intralesional therapies for melanoma

Daniel Y Wang  1 , Douglas B Johnson  1
Affiliations
Review

Advances in the development of intralesional therapies for melanoma

Daniel Y Wang et al. Melanoma Manag. 2016 Dec.

Abstract

Advances in immune therapy have changed the landscape of advanced melanoma treatment. Intralesional therapy is an important type of immune therapy due to its efficacy and safety, especially in the setting of locoregional metastases. These therapies induce frequent responses in injected lesions as well as distant nontreated lesions through a 'bystander' effect of priming an antitumor immune response. The culmination of nearly a century of innovation has led to the approval of the first US FDA approved intralesional therapy for melanoma in talimogene laherparepvec. Numerous efforts to combine intralesional therapies with systemic immune checkpoint inhibitors are ongoing, whereby a synergistic effect may continue to improve outcomes for patients.

Keywords: intralesional therapy; melanoma; talimogene laherparepvec.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure DB Johnson is on the advisory board for Genoptix and Bristol-Myers Squibb and has received research funding from Incyte. DY Wang has no conflicts of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Proposed mechanism for Talimogene laherparepvec.
DC: Dendritic cell.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016;66(1):7–30. - PubMed
    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008;58(2):71–96. - PubMed
    1. Read RL, Haydu L, Saw RP, et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann. Surg. Oncol. 2015;22(2):475–481. - PubMed
    1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. Relat. Res. 1991;(262):3–11. - PubMed
    1. The failure of the erysipelas toxins. J. Am. Med. Assoc. 1894;XXIII(24):919.

LinkOut - more resources